Omeros Corporation (OMER) Rises on Trial Data

Omeros Corporation (NASDAQ: OMER) rose 6.7% to $15.51 after the company reported data in OMS721 Phase 2 trial in renal diseases. Share volume was 935,000, compared to an all-day average of 483,000